Prostat Kanseri Tanısında Biparametrik Prostat Mr Sonrası Algısal Hedefli Prostat Biyopsinin Etkinliğinin Değerlendirilmesi
Küçük Resim Yok
Tarih
2018
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Maltepe Üniversitesi, Tıp Fakültesi
Erişim Hakkı
CC0 1.0 Universal
info:eu-repo/semantics/openAccess
info:eu-repo/semantics/openAccess
Özet
Amaç: Bu çalı?madaki amacımız; prostat kanseri tanısında biparametrik prostat MR sonrasında yapılan TRUS e?likli algısal hedefli prostat biyopsinin etkinliğinin değerlendirilmesidir. Gereç ve Yöntem: Bu prospektif çalı?mada, klinik olarak prostat kanseri ?üphesi (dijital rektal muayene (DRM) anormalliği veya prostat spesifik antijen (PSA) yüksekliği) mevcut ve transrektal ultrason (TRUS) e?liğinde standart prostat biyopsisi (SB) ve hedefli prostat biyopsisi (HB) yapılan 31 olgu çalı?ma grubu, son 5 yıl içerisinde merkezimizde SB yapılan benzer demografik (ya?) verilere ve ortalama PSA değerine sahip rastgele seçilen 31 olgu ise kontrol grubu olarak çalı?maya dahil edildi. Çalı?ma grubundaki olgulara ilk olarak biparametrik MR (bpMR) tetkiki yapıldı ve bpMR görüntüleri PI-RADS v2'ye göre değerlendirildi. Takibinde TRUS e?liğinde SB ve buna ek bpMR tetkikinde PI-RADS kategori 3 ve üzeri olan lezyonlardan HB yapıldı. Çalı?ma ve kontrol grubu olguların SB sonuçları ve çalı?ma grubu olguların SB ve HB'si sonuçları kar?ıla?tırıldı. Bulgular: 31 hastanın (ortalama ya?: 66 yıl, ortalama PSA seviyesi: 11.11 ng / mL) prostat kanseri (PCa) pozitiflik oranları SB için % 29 (n = 9) ve HB için% 48.4 (n = 15) (p <0, 05) olup, SB sonucu negatif olan 6 hastaya (% 19.4) HB ile PCa tanısı konuldu . Klinik anlamlı PCa (Gleason?7) oranları ise SB için% 25.8 (n = 8) ve HB için% 38.7 (n = 12) (P> 0,05) olup, SB sonucu negatif olan 4 hastaya (% 13.1) HB ile klinik anlamlı PCa tanısı konuldu . Sonuç: Prostat kanseri ?üphesi olan erkeklerde, bpMR sonrası yapılan algısal hedefli biyopsi, prostat kanseri ve klinik anlamlı prostat kanseri saptama oranlarını arttırmaktadır.
Objective: The aim of the study was to evaluate the efficacy of cognitive-targeted prostate biopsy after biparametric prostate MRI in the diagnosis of prostate cancer. Materials and Methods: This prospective study included 31 patients with informed consent who were clinic suspected of having PCa (an elevated prostate-specific antigen level or an abnormal digital rectal examination) and TRUS-guided standard prostate biopsy(SB) and cognitive targeted prostate biopsy (TB) were included in the study group and in the last 5 years, 31 randomly selected patients with similar demographic (age) and mean PSA values in our center were included in the study as control group. In the study group first biparametric MRI (bpMR) was performed. bpMR were evaluated according to PI-RADS v2. TRUS guided SB was performed all the patient and HB was performed who have PIRADS category 3 or greater lesion in the bpMRI. The SB results of the study and control groups were compared and SB and TB results of the study group were compared. Results: Among 31 patients (median age: 66 years; mean prostate specific antigen level:11.11 ng/mL), positivity rate for PCa was 29% (n = 9) for SB and 48.4% (n = 15) for TB (p<0,05). 6 patients (19.4%) with a negative SB score were diagnosed PCa with HB. For clinically significant PCa (Gleason?7) was 25.8% (n = 8) for SB and 38.7% (n = 12) for TB (P >0,05). Clinically significant PCa was diagnosed through TB in 4 patients (13.1%) with negative SB results. Conclusion: In men with suspected prostate cancer, for detection of prostate cancer, before biopsy bpMR evaluation and than cognitive targeted biopsy was better than standard biopsy
Objective: The aim of the study was to evaluate the efficacy of cognitive-targeted prostate biopsy after biparametric prostate MRI in the diagnosis of prostate cancer. Materials and Methods: This prospective study included 31 patients with informed consent who were clinic suspected of having PCa (an elevated prostate-specific antigen level or an abnormal digital rectal examination) and TRUS-guided standard prostate biopsy(SB) and cognitive targeted prostate biopsy (TB) were included in the study group and in the last 5 years, 31 randomly selected patients with similar demographic (age) and mean PSA values in our center were included in the study as control group. In the study group first biparametric MRI (bpMR) was performed. bpMR were evaluated according to PI-RADS v2. TRUS guided SB was performed all the patient and HB was performed who have PIRADS category 3 or greater lesion in the bpMRI. The SB results of the study and control groups were compared and SB and TB results of the study group were compared. Results: Among 31 patients (median age: 66 years; mean prostate specific antigen level:11.11 ng/mL), positivity rate for PCa was 29% (n = 9) for SB and 48.4% (n = 15) for TB (p<0,05). 6 patients (19.4%) with a negative SB score were diagnosed PCa with HB. For clinically significant PCa (Gleason?7) was 25.8% (n = 8) for SB and 38.7% (n = 12) for TB (P >0,05). Clinically significant PCa was diagnosed through TB in 4 patients (13.1%) with negative SB results. Conclusion: In men with suspected prostate cancer, for detection of prostate cancer, before biopsy bpMR evaluation and than cognitive targeted biopsy was better than standard biopsy
Açıklama
Anahtar Kelimeler
Prostat kanseri, bpMR, PI-RADS v2, mpMR, Prostat biyopsi, Prostate cancer, Prostate biopsy
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Ünal Özdemir, N. (2018). Prostat Kanseri Tanısında Biparametrik Prostat Mr Sonrası Algısal Hedefli Prostat Biyopsinin Etkinliğinin Değerlendirilmesi. (Yayımlanmamış Uzmanlık Tezi). Maltepe Üniversitesi, Tıp Fakültesi, İstanbul.
